#1 Clinical Trials Search in Europe

Conjunctivitis allergic – Trials in Disease

Go back

Clinical Trials for Allergic Conjunctivitis

There are currently 20 ongoing clinical trials investigating treatments for allergic conjunctivitis, a condition causing eye irritation, redness, and itching due to allergen exposure. These studies are evaluating various immunotherapy approaches and medications to reduce allergic symptoms, primarily focusing on allergies to pollen (grass, birch, olive, and cypress tree pollen) and house dust mites. Most trials involve sublingual or subcutaneous immunotherapy treatments, though one study examines eye drops for direct symptom relief. (Also known as: Allergic Rhinoconjunctivitis, Seasonal Allergic Conjunctivitis, Allergic Rhinitis with Conjunctivitis)

Clinical trial locations

Study of CLU-RX-PHL injection therapy for patients with moderate to severe grass pollen allergy to find the most effective and safe dose

This study is testing a treatment called CLU-RX-PHL for people with moderate to severe allergic reactions to grass pollen. The condition causes symptoms like nasal congestion, runny nose, and eye irritation during the grass pollen season.

Main inclusion criteria: Participants must be between 18 and 65 years old and have experienced moderate-to-severe symptoms affecting the nose and eyes for at least two years. They must show positive reactions to timothy grass pollen through skin tests and blood tests. Those with well-controlled mild-to-moderate asthma may participate, provided their lung function is greater than 80% of the normal predicted value.

Main exclusion criteria: Individuals with a history of severe allergic reactions requiring emergency treatment cannot participate. Those who have received grass pollen immunotherapy within the past five years are excluded, as are pregnant women or those planning pregnancy during the study period. Participants with uncontrolled asthma or other significant medical conditions affecting heart, liver, or kidneys are not eligible.

Main focus: The study aims to determine which dose of CLU-RX-PHL (high, medium, or low) works best and is most tolerable for patients. The treatment is administered as injections under the skin over 50 weeks. Effectiveness is measured by tracking symptom severity and medication use during grass pollen season through an electronic diary.

Investigational drug: CLU-RX-PHL is an immunotherapy treatment given as subcutaneous injections containing modified grass pollen extract. This cluster immunotherapy helps the immune system gradually become less sensitive to grass pollen, potentially reducing symptoms and the need for additional allergy medications.

Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma

This trial is evaluating a vaccine containing modified allergen extracts from six types of grasses and Juniperus oxycedrus for treating allergic reactions affecting the nose and eyes. Some participants may also have mild to moderate asthma.

Main inclusion criteria: Participants must be between 12 and 65 years old with confirmed allergies to grass and cupressaceae (the plant family that includes Juniperus oxycedrus) for at least 12 months. They must show positive skin test reactions and specific blood antibody levels indicating allergies to these plants. Women of childbearing age must have negative pregnancy tests and agree to use reliable birth control methods.

Main exclusion criteria: Those with severe uncontrolled asthma cannot participate. Pregnant or breastfeeding women are excluded, as are individuals currently participating in other clinical trials. Those with histories of severe allergic reactions or recent use of certain allergy treatments may not be eligible.

Main focus: The study monitors symptom severity and medication use during the grass and cupressaceae pollen seasons (January through June) over 12 months. Participants record symptoms using a smartphone app. The trial also evaluates quality of life, days free from symptoms and medication, and any asthma flare-ups.

Investigational drug: The vaccine contains polymerized allergen extracts from six grass species and Juniperus oxycedrus, administered through subcutaneous injections. This immunotherapy aims to reduce allergic responses by gradually exposing the immune system to these allergens.

Study on the Effectiveness and Safety of Sublingual MM09 for Patients Aged 12-65 with Allergies to House Dust Mites and Rhinitis/Rhinoconjunctivitis with or without Asthma

This trial is testing MM09, a sublingual spray treatment for allergies to house dust mites that cause nasal and eye symptoms. Some participants may also have mild to moderate controlled asthma.

Main inclusion criteria: Participants must be between 12 and 65 years old with confirmed moderate to severe symptoms for at least one year. They must demonstrate positive skin tests showing reactions of at least 5 mm to dust mite allergens and have specific blood antibody levels above 3.5 kU/L. Participants must own smartphones to record symptoms and must not be sensitized to certain other allergens like molds or cockroaches.

Main exclusion criteria: Those with severe uncontrolled asthma cannot participate. Other serious health conditions that might interfere with the study exclude participation, as does pregnancy or breastfeeding. Individuals with histories of severe allergic reactions or recent use of certain allergy treatments may not be eligible.

Main focus: The study evaluates symptom reduction and medication use over 12 months. Participants use the sublingual spray daily and record their symptoms and medication use in electronic diaries. The trial monitors quality of life, days free from symptoms, and any asthma-related events.

Investigational drug: MM09 is a sublingual immunotherapy spray applied under the tongue. It contains dust mite allergens (Dermatophagoides pteronyssinus and Dermatophagoides farinae) designed to gradually desensitize the immune system to these allergens, reducing allergic reactions over time.

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

This study focuses on testing PQ Grass treatment in children and adolescents with seasonal allergies caused by grass pollen. The condition commonly causes symptoms like sneezing, runny nose, and itchy eyes during grass pollen season.

Main inclusion criteria: Participants must be between 5 and 16 years old at treatment start and have a history of moderate to severe seasonal allergies to grass pollen for at least one year (or since age 5). They must show positive skin test reactions of at least 3 mm to grass pollen and have specific allergy antibodies at class 2 or higher. Children must be able to perform breathing tests and have lung function at least 80% of expected values or meet specific breathing capacity ratios.

Main exclusion criteria: Children without seasonal allergies caused by grass pollen cannot participate. Those with other health conditions that might interfere with the study, taking certain medications that could affect results, or who have had severe allergic reactions to similar treatments in the past are excluded. Children unable to follow study procedures are not eligible.

Main focus: The study evaluates both short-term and long-term effectiveness of PQ Grass 27600 SU given as subcutaneous injections. The trial monitors symptom changes during grass pollen season and includes a treatment-free follow-up period to assess sustained benefits. Participants attend regular visits for assessments and monitoring.

Investigational drug: PQ Grass 27600 SU is administered as subcutaneous injections to treat seasonal allergies to grass pollen. This allergen immunotherapy aims to modify the immune system’s response to grass pollen allergens, reducing symptom severity over time.

Study of sublingual birch pollen extract (SLI-RX-BET) in different doses for patients with moderate to severe allergic rhinitis caused by birch pollen

This trial tests SLI-RX-BET, a sublingual spray containing birch pollen extract, for treating moderate to severe allergies caused by birch pollen. The condition causes nasal congestion, runny nose, and eye irritation during birch pollen season.

Main inclusion criteria: Participants must be between 18 and 65 years old with moderate-to-severe symptoms for at least two years. They must show positive skin prick tests with reactions of 3 mm or larger to birch pollen and have blood tests confirming birch pollen antibodies. Those with well-controlled mild-to-moderate asthma may participate if their lung function (FEV1) is greater than 70% of normal. Participants must be able to use electronic diaries to record symptoms.

Main exclusion criteria: Those with a history of severe allergic reactions or previous birch pollen immunotherapy within the past five years cannot participate. Current poorly controlled asthma, pregnancy, breastfeeding, or planning pregnancy during the study excludes participation. Individuals with serious heart, liver, or kidney disease, autoimmune diseases, or recent cancer are not eligible.

Main focus: The study compares three different doses of SLI-RX-BET (low, medium, and high) against placebo over approximately 10 months. Participants use the spray daily under the tongue and track symptoms and medication use in electronic diaries during birch pollen season. The trial includes quality of life assessments and nasal provocation testing before and after treatment.

Investigational drug: SLI-RX-BET is a sublingual immunotherapy spray applied under the tongue containing birch pollen extract. This treatment aims to help the immune system become less sensitive to birch pollen by gradually exposing it to small amounts of the allergen, potentially reducing symptoms and medication needs.

Study of sublingual immunotherapy with Phleum pratense pollen extract spray in patients with moderate to severe grass pollen allergic rhinitis

This trial evaluates SLI-RX-PHL, a sublingual spray containing timothy grass pollen extract, for treating moderate to severe allergies causing nasal and eye symptoms during grass pollen season.

Main inclusion criteria: Participants must be between 18 and 65 years old with moderate-to-severe symptoms for at least two years. They must show positive skin prick tests, blood tests confirming grass pollen antibodies, and positive nasal allergen challenge tests. Those with well-controlled mild-to-moderate asthma may participate if their lung function (FEV1) is greater than 70% of normal. Participants must be willing to use electronic diaries for symptom tracking.

Main exclusion criteria: Those under 18 or over 65 years old cannot participate. History of severe allergic reactions requiring emergency treatment, current participation in other clinical trials, or pregnancy/planning pregnancy excludes participation. Poorly controlled asthma, current treatment with interfering medications, or serious medical conditions affecting heart, liver, or kidneys make individuals ineligible.

Main focus: The study tests three different doses of SLI-RX-PHL (low, medium, and high) against placebo over up to 50 weeks. The spray is applied under the tongue and participants record daily symptoms, medication use, and overall discomfort on a 0-10 scale during grass pollen season. The trial includes quality of life assessments and nasal provocation tests before and after treatment.

Investigational drug: SLI-RX-PHL is a sublingual immunotherapy spray containing Phleum pratense pollen extract. This treatment works by gradually desensitizing the immune system to grass pollen allergens through regular exposure under the tongue, helping to reduce allergic reactions during grass pollen season.

Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

This trial tests a vaccine containing modified allergen extracts from six grass types and olive pollen for treating allergies affecting the nose and eyes. Participants may also have mild to moderate asthma.

Main inclusion criteria: Participants must be between 12 and 65 years old with confirmed histories of allergies to grass and olive tree pollen. They must show positive skin prick test reactions to mixtures of grass or olive tree pollen and have specific blood antibody levels (IgE) above certain thresholds indicating allergies. Women of childbearing age must have negative pregnancy tests and agree to use reliable birth control. Participants must own smartphones for symptom recording and not react positively to certain other allergens.

Main exclusion criteria: Those with severe uncontrolled asthma cannot participate. Pregnant or breastfeeding women, those currently in other clinical trials, and individuals with histories of severe allergic reactions to similar treatments are excluded. Those with drug or alcohol abuse histories or unable to follow study procedures are ineligible.

Main focus: The study monitors symptoms and medication use during grass and olive tree pollen seasons (April, May, and June) over 12 months. Participants receive subcutaneous injections and record symptoms using smartphones. The trial evaluates overall symptom scores, days free from symptoms and medication, asthma exacerbations, and quality of life.

Investigational drug: The vaccine contains polymerized allergen extracts from six grasses and olive pollen, administered through subcutaneous injections. This immunotherapy gradually desensitizes the immune system to these allergens by modifying the immune response, aiming to reduce allergic reactions.

Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

This trial evaluates a mannan-conjugated allergoid vaccine for treating allergies to house dust mites that cause nasal and eye symptoms. Some participants may also have mild to moderate controlled asthma.

Main inclusion criteria: Participants must be between 12 and 65 years old with moderate-to-severe symptoms for at least one year. They must show positive skin prick tests with reactions of at least 5 mm diameter to dust mite allergens and have specific blood antibody levels of at least 3.5 kU/L. Participants need to record symptoms and medication use in diaries and show combined symptom and medication scores of at least 2 out of 6 for at least 10 days. Women of childbearing age must have negative pregnancy tests and agree to use effective birth control.

Main exclusion criteria: Those without allergies to the specified dust mites or without moderate-to-severe persistent symptoms cannot participate. Participants younger than 12 or older than 65 are excluded, as are those considered part of vulnerable populations needing special protection.

Main focus: The study compares the mannan-conjugated allergoid vaccine (3,000 mTU/mL dose) administered through subcutaneous injections against placebo. Participants maintain diaries recording symptoms and medication use throughout the trial. The study monitors various symptom scores related to nasal, eye, and asthma symptoms, along with immunological parameters and quality of life assessments.

Investigational drug: EP-088_MM09 is a subcutaneous injection containing modified proteins from dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae). This immunotherapy aims to help the body become less sensitive to dust mites over time by gradually exposing the immune system to these allergens.

Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

This trial tests a mannan-conjugated allergoid vaccine given as subcutaneous injections for treating dust mite allergies causing nasal and eye symptoms. Participants may also have mild to moderate controlled asthma.

Main inclusion criteria: Participants must be between 12 and 65 years old with moderate-severe symptoms for at least one year. They must show positive skin prick tests with reactions of at least 5 mm to dust mite allergens and have specific blood antibody levels of at least 3.5 kU/L. Participants need combined symptom and medication scores of at least 2 out of 6 for at least 10 days. Women of childbearing age must have negative pregnancy tests and agree to use highly effective birth control methods.

Main exclusion criteria: Those not allergic to the specified dust mites or without moderate-to-severe persistent symptoms cannot participate. Participants younger than 12 or older than 65 are excluded, as are those considered vulnerable populations.

Main focus: The study evaluates the vaccine (3,000 mTU/mL dose) administered subcutaneously over approximately one year. Participants record symptoms and medication use in electronic or paper diaries. The trial monitors various symptom and medication scores, quality of life assessments, and immunological parameters in blood samples.

Investigational drug: EP-088_MM09 contains modified proteins from dust mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered through subcutaneous injections. This allergen immunotherapy aims to reduce allergic reactions by gradually desensitizing the immune system to dust mite allergens.

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

This trial evaluates Pollinex Quattro Plus 1.0 mL Birch for treating seasonal allergies caused by birch pollen, which cause symptoms like sneezing, blocked nose, and itchy eyes.

Main inclusion criteria: Participants must be between 18 and 65 years old with birch-specific blood antibody levels of 0.71 kUA/L or higher. They must have lung function tests (FEV1 and PEFR) at least 70% of expected values. Participants need a history of moderate to severe symptoms for at least two years despite using allergy medications like antihistamines or nasal sprays. They must show positive skin prick tests to both histamine and birch pollen. Females of childbearing potential must agree to use birth control as required.

Main exclusion criteria: Those without seasonal allergies caused by birch pollen cannot participate. Individuals not within the specified age range, unwilling to follow study procedures, or with other medical conditions that might interfere are excluded. Current participation in another clinical trial, history of severe allergic reactions, pregnancy, breastfeeding, or known allergies to study medication components make individuals ineligible.

Main focus: The study evaluates PQ Birch administered through subcutaneous injections compared to placebo. Participants receive regular injections throughout the birch pollen season. The trial monitors symptom changes, medication use, and quality of life during peak allergy times. Regular assessments include physical examinations, blood tests, and lung function tests.

Investigational drug: PQ Birch is administered as subcutaneous injections and works by modulating the immune system’s response to birch pollen. This allergen immunotherapy aims to reduce allergic reactions by helping the body gradually develop tolerance to birch pollen allergens.

Study of CLU-RX-BET injection therapy for patients with moderate to severe birch pollen allergies

This study tests CLU-RX-BET for treating moderate to severe birch pollen allergies causing nasal congestion, runny nose, and eye irritation during birch pollen season.

Main inclusion criteria: Participants must be between 18 and 65 years old with moderate-to-severe symptoms for at least two years. They must show positive skin prick tests, blood tests confirming birch pollen allergy, significant symptom history during birch pollen season, and positive nasal exposure tests. Those with well-controlled mild-to-moderate asthma may participate if their lung function (FEV1) is greater than 80% of normal. Participants must be able to use electronic diaries for daily symptom recording.

Main exclusion criteria: History of severe allergic reactions or previous birch pollen immunotherapy within the past five years excludes participation. Current uncontrolled asthma, other significant respiratory conditions, pregnancy or planning pregnancy, participation in another clinical trial within 30 days, autoimmune diseases, or serious medical conditions compromising safety make individuals ineligible. Use of systemic corticosteroids within the past three months or inability to follow study procedures also exclude participation.

Main focus: The study compares three doses of CLU-RX-BET (high, medium, and low) against placebo over 50 weeks. Participants receive subcutaneous injections containing modified birch pollen extract treated with glutaraldehyde. The trial tracks symptom severity and medication use during birch pollen season through electronic diaries. Assessments include quality of life questionnaires, visual scale ratings, and nasal provocation tests before and after treatment.

Investigational drug: CLU-RX-BET is a subcutaneous immunotherapy containing modified birch pollen allergens. This cluster immunotherapy helps the immune system gradually become less sensitive to birch pollen by building tolerance more quickly than traditional immunotherapy approaches.

Summary

The 20 ongoing clinical trials for allergic conjunctivitis demonstrate a strong focus on allergen-specific immunotherapy approaches, with the majority of studies investigating treatments for pollen allergies (grass, birch, olive, and cypress) and house dust mites. Germany hosts the largest number of trials (11), followed by Spain (9) and Poland (5), reflecting significant research activity in Central and Western Europe.

Most trials employ either subcutaneous injections or sublingual administration routes for immunotherapy. These studies predominantly target moderate to severe cases affecting both the nose and eyes, often including participants with controlled mild-to-moderate asthma. The trials typically span 12 months or longer, monitoring symptoms during peak allergen seasons.

Several studies focus on dose-finding for new immunotherapy products, comparing multiple dose levels against placebo to establish optimal treatment regimens. Common outcome measures include combined symptom and medication scores, quality of life assessments, and days free from symptoms or medication.

Only one trial evaluates a non-immunotherapy approach: ketotifen eye drops for direct symptom relief in Italy. This represents a different treatment strategy focused on immediate symptom management rather than long-term immune system modification.

The predominance of immunotherapy trials reflects the field’s emphasis on disease-modifying treatments that address underlying allergic mechanisms rather than merely controlling symptoms. These studies aim to provide lasting relief and reduce dependence on daily symptom-relief medications.

Ongoing Clinical Trials on Conjunctivitis allergic

  • Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Testing Intralymphatic Allergen Immunotherapy for Teenagers and Adults with Grass Pollen Allergy Causing Hay Fever or Asthma

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Italy

  • Study on the Safety and Effectiveness of Subcutaneous Immunotherapy with Der p 1, Der p 2, and Der p 23 Allergens for Patients with Allergic Rhinitis or Rhinoconjunctivitis

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Spain

More information about
Conjunctivitis allergic:

Connected medications: